Trials / Conditions / Refractory WHO Grade 2 Glioma
Refractory WHO Grade 2 Glioma
3 registered clinical trials studyying Refractory WHO Grade 2 Glioma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating NCT04320888 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alter NCT04284774 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutat NCT04195555 | National Cancer Institute (NCI) | Phase 2 |